Abstract | BACKGROUND & AIMS: METHODS: Indirect immunofluorescence was used to identify ANAs in 492 PBC patients. chi2 and Kaplan-Meier analyses were used to examine the association between ANAs and liver failure. RESULTS: A greater percentage of ANA-positive, compared to ANA-negative, PBC patients developed liver failure (41% vs 25%, P = .005). The presence of anti-centromere antibodies was associated with liver failure (anti-centromere antibody positive vs negative, 58% vs 33%, P = .001). The time to liver failure was shorter in ANA-positive, compared with ANA-negative, patients (log rank score 5.8, P = .02). After 8.9 years (the median follow-up for patients without liver failure), 68% of ANA-positive and 81% of ANA-negative patients were free of liver failure. Anti-centromere antibodies were also associated with a shorter time to liver failure (log rank score 8.4, P = .004). After 8.9 years, 52% of anti-centromere antibody positive and 74% of anti-centromere antibody negative patients were without liver failure. CONCLUSIONS:
|
Authors | Wei-Hong Yang, Jiang Hong Yu, Ayako Nakajima, Donna Neuberg, Keith Lindor, Donald B Bloch |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 2
Issue 12
Pg. 1116-22
(Dec 2004)
ISSN: 1542-3565 [Print] United States |
PMID | 15625657
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Antinuclear
- Biomarkers
|
Topics |
- Antibodies, Antinuclear
(blood)
- Biomarkers
(blood)
- Centromere
(immunology)
- Cohort Studies
- Female
- Fluorescent Antibody Technique, Indirect
- Follow-Up Studies
- Humans
- Liver Cirrhosis, Biliary
(immunology)
- Liver Failure
(immunology)
- Male
- Middle Aged
- Risk Assessment
(methods)
|